Belmin J, Valensi P
Service de Médecine Interne Gériatrique, Hôpital René Muret-Bigottini-Assistance Publique-Hôpitaux de Paris, France.
Drugs Aging. 1996 Jun;8(6):416-29. doi: 10.2165/00002512-199608060-00003.
The prevalence of diabetes mellitus increases markedly with age. Furthermore, advancing age is a strong risk factor for diabetic neuropathy, independent of the duration of diabetes mellitus and glycaemic control. Several biological changes occurring during the aging process may account for the facilitating effect of age on diabetic neuropathy. These include an increase in the production of advanced glycosylation end-products (AGEs), a defect in the polyol pathway, nerve vascular alterations and impaired resistance to oxidative stress. The clinical diagnosis of diabetic neuropathy is often difficult in elderly patients. The relationship between symptoms and neuropathy and that between neuropathy and diabetes mellitus are more difficult to ascertain in elderly patients due to age-related changes in the peripheral and autonomic nervous system and associated diseases frequently encountered in this population. Diagnosis of diabetic neuropathy is based on nerve conduction studies, vibratory perception threshold determination and assessment of autonomic function. For most of these tests, reference values are markedly influenced by age and their interpretation should use carefully age-adjusted reference intervals. Identification of peripheral diabetic neuropathy indicates a high risk of foot complications, such as ulcers and gangrene, often resulting in amputation, whereas cardiovascular autonomic neuropathy is associated with an increased risk of postural hypotension and coronary events. All these risks increase markedly with aging. Therapeutic trials in elderly patients with diabetic neuropathy are lacking. Treatment of diabetic neuropathy consists of achievement of better glycaemic control and treatment of symptoms related to neuropathy. Specific treatments capable of preventing or curing neuropathy are under investigation. The interesting results obtained with aldose reductase inhibitors in animal studies contrast with disappointing results in patients with diabetes mellitus. Other metabolic approaches, like antioxidants and gamma-linolenic acid, seem promising. Clinical complications of diabetic neuropathy in the elderly are often severe. Early detection is required, since at the present time a preventive approach is the most effective way to avoid or postpone debilitating complications. More research is needed to make effective curative treatments of diabetic neuropathy available.
糖尿病的患病率随年龄显著增加。此外,年龄增长是糖尿病神经病变的一个重要危险因素,与糖尿病病程和血糖控制无关。衰老过程中发生的一些生物学变化可能解释了年龄对糖尿病神经病变的促进作用。这些变化包括晚期糖基化终产物(AGEs)生成增加、多元醇途径缺陷、神经血管改变以及抗氧化应激能力受损。老年患者的糖尿病神经病变临床诊断往往困难。由于外周和自主神经系统的年龄相关变化以及该人群中经常遇到的相关疾病,老年患者中症状与神经病变之间以及神经病变与糖尿病之间的关系更难确定。糖尿病神经病变的诊断基于神经传导研究、振动觉阈值测定和自主神经功能评估。对于这些测试中的大多数,参考值受年龄影响显著,其解读应使用经过仔细年龄调整的参考区间。外周糖尿病神经病变的识别表明足部并发症(如溃疡和坏疽)风险高,常导致截肢,而心血管自主神经病变与体位性低血压和冠状动脉事件风险增加有关。所有这些风险都随着年龄增长而显著增加。老年糖尿病神经病变患者缺乏治疗试验。糖尿病神经病变的治疗包括更好地控制血糖以及治疗与神经病变相关的症状。能够预防或治愈神经病变 的特异性治疗正在研究中。醛糖还原酶抑制剂在动物研究中获得的有趣结果与糖尿病患者中令人失望的结果形成对比。其他代谢方法,如抗氧化剂和γ-亚麻酸,似乎很有前景。老年糖尿病神经病变的临床并发症往往很严重。需要早期检测,因为目前预防方法是避免或推迟使人衰弱的并发症的最有效方法。需要更多研究以提供有效的糖尿病神经病变治疗方法。